A polypeptide TDI-18 and its use
The level of serum inflammatory factors is reduced through the peptide TDI-18, which solves the problems of high mortality and serious inflammatory response in intensive care unit sepsis, significantly improves the treatment efficiency and patient prognosis, and improves organ function.
Patent Information
- Application Number
- CN202410301870.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-17
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-03-17
AI Technical Summary
The prior art has problems with high lethality and severe inflammatory response in the treatment of sepsis in intensive care unit, and lacks effective treatment methods to reduce serum inflammatory factors and improve organ function.
Provided a polypeptide TDI-18, whose amino acid sequence is YGRKKRRQRRRHWEGPATCKYEQILMNVF, is prepared by solid phase synthesis method, and can reduce serum TNF-α, IL-6 and hs-CRP levels, and is used to assist in the treatment of intensive care unit sepsis and improve Functions of the heart, liver, kidney and other organs.
The peptide TDI-18 significantly reduced the serum inflammatory factor level in patients, improved the treatment efficiency, reduced the hospitalization time and risk of death, improved the heart, liver and kidney functions, and significantly improved the survival rate and clinical rate of patients with severe sepsis. symptom.
Smart Images

Figure CN117946286B_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of polypeptides, and in particular to a polypeptide TDI-18 and uses thereof. [Background technology]
[0002] Sepsis in the intensive care unit (ICU) is a life-threatening infectious disease. With the increasing incidence of the disease, it has become one of the major problems that need to be solved in the medical and health field. The development of sepsis is caused by the body's systemic inflammatory response syndrome to the source of infection, which may lead to serious adverse reactions such as multiple organ failure, and patients have a high risk of mortality. Although some progress has been made in the treatment and management of sepsis in recent years, many challenges still exist, especially for the treatment of critically ill patients. At present, the treatment strategies for sepsis mainly include early antibiotic treatment, mechanical ventilation and supportive treatment for critically ill patients, but the high mortality rate of the disease remains a serious problem.
[0003] Therefore, it is crucial to seek new treatments to improve the survival rate and clinical symptoms of patients with sepsis. [Summary of the invention]
[0004] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a polypeptide TDI-18 and its use. To achieve the above purpose, the present invention provides the following technical solutions:
[0005] In a first aspect, the present invention provides a polypeptide TDI-18, the amino acid sequence of which is SEQ ID No. 1: YGRKKRRQRRRHWEGPATCKYEQILMNVF, named TDI-18.
[0006] Preferably, the N-terminus of the polypeptide is connected to a leader transmembrane peptide of 11 amino acids, whose amino acid sequence is SEQ ID No. 2: YGRKKRRQRRR, which is used to carry the following 18 amino acids to penetrate the cell membrane, and the following 18 amino acids SEQ ID No. 3: HWEGPATCKYEQILMNVF are the main body of the function.
[0007] Preferably, the polypeptide is prepared by solid phase synthesis.
[0008] Preferably, the polypeptide can reduce serum TNF-α, IL-6 and hs-CRP levels.
[0009] Preferably, the polypeptide is capable of reducing the levels of ALT, AST, BUN, Scr, LDH and CK.
[0010] In a second aspect, the present invention provides use of the above-mentioned polypeptide TDI-18 in the preparation of a drug for auxiliary treatment of sepsis in an intensive care unit.
[0011] The above-mentioned medicine comprises: a therapeutically effective dose of the polypeptide TDI-18 and pharmaceutically acceptable excipients.
[0012] The difference between the present invention and the prior art is that the present invention achieves the following technical effects:
[0013] The present invention has found through experiments that polypeptide TDI-18 can reduce serum TNF-α, IL-6 and hs-CRP levels, can reduce ALT, AST, BUN, Scr, LDH and CK levels, and can be used for auxiliary treatment of sepsis in intensive care units, effectively reduce the level of serum inflammatory factors in patients, improve the function of patients' heart, liver, kidney and other organs, and reduce patients' hospitalization time and risk of death.
Brief Description of the Drawings
[0014] Figure 1 It is a comparison chart of inflammatory factors and APACHEⅡ scores before and after treatment between the observation group and the control group of the present invention.
[0015] Figure 2 It is a comparison chart of biochemical indices of heart, liver and kidney function between the observation group and the control group before and after treatment. [Specific implementation method]
[0016] The technical scheme and technical effect of the present invention are described in detail below in conjunction with specific embodiments and accompanying drawings. Experimental methods without specifying specific conditions are usually according to conventional conditions, such as the conditions described in textbooks and experimental guides, or according to the conditions recommended by the manufacturer, which are well known or easily known to those of ordinary skill in the art. The materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial channels. The following examples are only preferred embodiments of the present invention and do not limit the present invention. For those skilled in the art, the present invention may have various changes and variations, and any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
[0017] Example 1
[0018] The polypeptide TDI-18 of the present application (amino acid sequence: YGRKKRRQRRRHWEGPATCKYEQ ILMNVF) was synthesized by the inventors using a solid phase synthesis method, with the sequence: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-His-Trp-Glu-Gly-Pro-Ala-Thr-Cys-Lys-Tyr-Glu-Gln-Ile-Leu-Met-Asn-Val-Phe. The molecular weight of the polypeptide TDI-18 is 3328.04 Da, and the HPLC purity is >99%.
[0019] The applicant adopts the solid phase synthesis method as follows:
[0020] Step 1: Select 2-chlorotrityl chloromethyl resin as the solid phase carrier;
[0021] Step 2: Connect the first amino acid (Tyr) to the solid support, use 1-hydroxybenzotriazolone and N,N'-diisopropylformamide as activators, and adjust the base conditions;
[0022] Step 3: Fmoc deprotection using 20% piperidine / DMF solution;
[0023] Step 4: Repeat steps 2 and 3, and add the remaining amino acids in sequence to ensure that the coupling reaction of each amino acid is complete;
[0024] Step 5: Hardening at appropriate positions in the synthetic sequence to protect unreacted active sites;
[0025] Step 6: After the synthesized peptide is fixed on the support, an elution step is performed to remove the remaining protecting groups and unreacted amino acids;
[0026] Step 7: Purify the polypeptide, for example, by countercurrent chromatography or high performance liquid chromatography;
[0027] Step 8: Finally, the peptide is structurally characterized using techniques such as mass spectrometry.
[0028] It should be noted that, depending on different situations, the polypeptide TDI-18 of the present application can also be synthesized using other conventional solid phase synthesis methods.
[0029] Example 2
[0030] 1.1 Grouping
[0031] 92 patients with severe sepsis were selected as research subjects, and basic information such as patient gender, age, course of disease, primary disease, infection status, etc. were collected. The above patients were all from the First Affiliated Hospital of Soochow University. After review and approval by the hospital ethics committee, all patients signed informed consent. According to the different treatment interventions received by the patients, they were divided into a control group and an observation group, with 46 cases in each group. Patients in the control group received conventional treatment interventions, and patients in the observation group (ie, the treatment group) were treated with the peptide TDI-18 of this application as an auxiliary treatment on the basis of the treatment of the control group patients.
[0032] 1.2 Inclusion and Exclusion Criteria
[0033] Inclusion criteria: ① The diagnostic criteria refer to the latest relevant standards formulated by the International Sepsis Conference, with bacteriological culture evidence; ② The patient is over 18 years old and the onset time is within 6 hours; ③ The patient has not received antibiotics, hormones, immunoglobulin or other similar drugs and preparations in the past three months; ④ The patient's blood routine and heart, liver and kidney electrochemical indicators have different degrees of abnormal changes when admitted to the hospital; ⑤ The patient is evaluated by the doctor and confirmed to need to be admitted to the intensive care unit for treatment.
[0034] Exclusion criteria: ① Exclude patients with combined blood system or immune system diseases; ② Exclude patients with combined metabolic diseases; ③ Exclude patients with severe organ dysfunction; ④ Exclude patients with tumor diseases; ⑤ Exclude patients with cognitive impairment and mental illness; ⑥ Exclude patients with allergic constitution or severe skin diseases; ⑦ Exclude patients with rheumatoid arthritis, connective tissue disease or limb disability; ⑧ Exclude pregnant or lactating women; ⑨ Exclude patients who are allergic to the drugs involved in the study or who are receiving other drug treatments at the same time.
[0035] 1.3 Administration
[0036] Patients in the control group received conventional treatment intervention, which refers to symptomatic treatment for the patient's primary disease, including fluid resuscitation, anti-infection, mechanical ventilation, continuous renal replacement therapy, etc., to actively maintain the patient's water, electrolyte and acid-base balance.
[0037] The patients in the observation group were given the polypeptide TDI-18 of the present application as an auxiliary treatment on the basis of the treatment of the patients in the control group. The conventional treatment intervention methods of the observation group were consistent with those of the control group. On this basis, the polypeptide TDI-18 of the present application was taken, with each dose of 30g taken with warm water, 3 times / d, for continuous treatment for 2 months.
[0038] 1.4 Observation indicators
[0039] (1) Clinical efficacy: Markedly effective: After treatment, the patient's clinical symptoms disappeared, systolic blood pressure ≥90 mmHg, and 1-hour urine volume ≥30 mL; Effective: After treatment, the patient's clinical symptoms were relieved, and the blood pressure increased by ≥10 mmHg compared with before treatment; Ineffective: After treatment, the patient's symptoms did not improve significantly or even worsened.
[0040] (2) Levels of inflammatory factors: Before and after treatment, 5 mL of fasting cubital venous blood was collected from the patients in the morning and centrifuged for examination. Serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected by enzyme-linked immunosorbent assay, and high-sensitivity C-reactive protein (hs-CRP) levels were detected by latex-enhanced immunoturbidimetry.
[0041] (3) Acute Physiology and Chronic Health Evaluation System II (APACHE II) score: The APACHE II scores of the two groups of patients were statistically compared before and after treatment. The score of the scale ranges from 0 to 71 points. The higher the score of the patient, the more serious the disease.
[0042] (4) Biochemical indicators of heart, liver, and kidney function: Before and after treatment, the first urine sample in the morning was collected from the patient, and the H-800 fully automatic urine analyzer was used to detect the patient's urea nitrogen (BUN) level; 10 mL of venous blood was drawn from the patient on an empty stomach, and the liquid was collected by conventional centrifugation for testing. The OLYMPUS AU640 fully automatic biochemical analyzer and fully automatic chemiluminescence enzyme immunoassay analyzer were used to detect the patient's alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Scr), lactate dehydrogenase (LDH), and creatine phosphokinase (CK) levels.
[0043] (5) Disease outcome and prognosis: The mechanical ventilation time, average hospital stay, ICU stay, MODS incidence, and 28-day mortality rate of the two groups of patients were recorded.
[0044] 1.5 Data Analysis
[0045] GraphPad Prism 8 was used for drawing; SPSS 22.0 was used for data analysis. For measurement data, the mean and standard deviation can be used to describe their distribution in this study, and t-test or analysis of variance can be used for statistical analysis. For count data, frequency and percentage can be used to describe their distribution, and chi-square test or Fisher's exact test can be used for statistical analysis. P < 0.05 indicates that the difference is statistically significant.
[0046] 2. Experimental results
[0047] 2.1 Basic data comparison
[0048] The basic data of the two groups of patients were comparable, and there was no significant difference between them (P>0.05). See Table 1 for details.
[0049] Table 1 Basic data comparison
[0050]
[0051] 2.2 Comparison of clinical efficacy
[0052] The total effective rate of the control group was 67.39%, and the total effective rate of the observation group was 86.96%. The total effective rate of the observation group was significantly higher than that of the control group (P < 0.05). See Table 2 for details.
[0053] Table 2 Comparison of clinical efficacy
[0054]
[0055]
[0056] 2.3 Comparison of inflammatory factors and APACHE II scores
[0057] like Figure 1 As shown in the figure, before treatment, the serum TNF-α, IL-6, hs-CRP levels and APACHEⅡ scores of the two groups of patients were compared (P>0.05); after treatment, the serum TNF-α, IL-6, hs-CRP levels and APACHEⅡ scores of the observation group were significantly lower than those of the control group (P<0.05).
[0058] Note: * indicates comparison P < 0.05.
[0059] 2.4 Comparison of biochemical indicators of heart, liver and kidney function
[0060] like Figure 2 As shown in the figure, before treatment, the levels of ALT, AST, BUN, Scr, LDH and CK of the two groups of patients were compared (P>0.05); after treatment, the levels of ALT, AST, BUN, Scr, LDH and CK of the observation group were significantly lower than those of the control group (P<0.05).
[0061] Note: * indicates comparison P < 0.05.
[0062] 2.5 Comparison of disease progression and prognosis
[0063] The mechanical ventilation time, average hospital stay and ICU stay in the observation group were significantly lower than those in the control group (P < 0.05). The incidence of MODS and 28-day mortality in the observation group were significantly lower than those in the control group (P < 0.05). See Table 3 for details.
[0064] Table 3 Comparison of disease outcome and prognosis
[0065]
[0066] 3. Conclusion
[0067] The results of this study showed that the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05); after treatment, the serum TNF-α, IL-6, hs-CRP levels and APACHEⅡ scores of the observation group were significantly lower than those of the control group (P < 0.05). The above research results show that the auxiliary application of the polypeptide TDI-18 of the present invention can improve the therapeutic effect of patients with severe sepsis, and it can reduce the excessive secretion of T'NF-α, IL-6, and hs-CRP in patients with severe sepsis, indicating that the polypeptide TDI-18 can effectively inhibit the generation and release of inflammatory mediators, thereby reducing the damage of inflammatory response to the body. After treatment, the ALT, AST, BUN, Scr, LDH, and CK levels of the observation group were significantly lower than those of the control group (P < 0.05). This result shows that the polypeptide TDI-18 of the present invention can effectively improve the liver, kidney, and heart function of patients with severe sepsis, which may be related to the ability of polypeptide TDI-18 to correct shock and hypoperfusion as soon as possible and prevent further damage to organs and tissue cells. In addition, the results of this study also showed that the mechanical ventilation time, ICU hospitalization time, average hospitalization time, MODS incidence and 28-day mortality rate of the observation group were significantly lower than those of the control group. This result suggests that adjuvant therapy with peptide TDI-18 can effectively restore blood supply to important organs, thereby promoting the recovery of patient prognosis.
[0068] Therefore, the polypeptide TDI-18 of the present invention has significant clinical efficacy in assisting the treatment of sepsis in the intensive care unit. It can effectively reduce the level of serum inflammatory factors in patients, improve the functions of the patient's heart, liver, kidney and other organs, and reduce the patient's hospitalization time and risk of death.
[0069] The embodiments described above are merely descriptions of preferred implementations of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A polypeptide TDI-18, characterized in that: The amino acid sequence of the polypeptide is SEQ ID No. 1: YGRKKRRQRRRHWEGPATCKYEQILMNVF, and is named TDI-18.
2. The polypeptide TDI-18 according to claim 1, characterized in that: The N-terminus of the polypeptide is connected to a leading transmembrane peptide of 11 amino acids, whose amino acid sequence is SEQ ID No.2: YGRKKRRQRRR, which is used to carry the following 18 amino acids to penetrate the cell membrane. The following 18 amino acids SEQ ID No.3: HW EGPATCKYEQILMNVF are the main body of the function.
3. The polypeptide TDI-18 according to claim 1, characterized in that: The polypeptide is prepared by solid phase synthesis.
4. The polypeptide TDI-18 according to claim 1, characterized in that The polypeptide can reduce serum TNF-α, IL-6 and hs-CRP levels.
5. The polypeptide TDI-18 according to claim 1, characterized in that The polypeptide can reduce the levels of ALT, AST, BUN, Scr, LDH and CK.
6. Use of the polypeptide TDI-18 as claimed in claim 1 in the preparation of a drug for auxiliary treatment of sepsis in an intensive care unit.
7. The use according to claim 6, characterized in that The medicine comprises: a therapeutically effective dose of the polypeptide TDI-18 and pharmaceutically acceptable excipients.
